Company news
Tarsus Pharmaceuticals, Inc. news in 2022
Tarsus Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
Tarsus Added to NASDAQ Biotechnology Index
December 15, 2022
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
December 14, 2022
Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements
November 8, 2022
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
October 24, 2022
Tarsus Announces Transition Plans for Board of Directors
October 10, 2022
Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair
October 5, 2022
Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis
September 28, 2022
Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings
September 26, 2022
Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis
September 6, 2022
Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements
August 10, 2022
Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease
August 4, 2022
Tarsus to Present at the Jefferies 2022 Healthcare Conference
May 26, 2022
Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements
May 9, 2022
Tarsus to Present at Bank of America 2022 Healthcare Conference
May 5, 2022
Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting
May 4, 2022
Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock
May 2, 2022
Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock
May 1, 2022
Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year
May 1, 2022
Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis
April 28, 2022
Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting
April 25, 2022
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements
March 13, 2022
Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer
February 2, 2022
Tarsus to Host Eye Care Leaders Webcast on Unmet Needs in Demodex Blepharitis and Potential of TP-03
February 1, 2022
Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures $175 Million Credit Facility
February 1, 2022
Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors
January 3, 2022
Decks in 2022
- Corporate Update (May 2022)
Corporate update · 37 slides · May 2, 2022
- Corporate Update (May 2022)
Corporate update · 38 slides · May 2022
- Corporate Update (February 2022)
Corporate update · 39 slides · Feb 8, 2022